Overview

A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-05-19
Target enrollment:
Participant gender:
Summary
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Tallac Therapeutics